Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.43 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | PNP | P00491 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 2/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.40 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19866584 | 0.93 | POLG (0.43) | POLGFUT5TGM2PNPNT5E | |
| SCHEMBL18879874 | 0.89 | POLG (0.47) | POLGFUT5TGM2PNPNT5E | |
| SCHEMBL21385610 | 0.89 | FUT5 (0.47) | POLGFUT5TGM2PNPNT5E | |
| SCHEMBL21385648 | 0.89 | FUT5 (0.47) | POLGFUT5TGM2PNPNT5E | |
| SCHEMBL19590288 | 0.89 | KRAS (0.48) | POLGFUT5TGM2PNPNT5E | |
| SCHEMBL19590186 | 0.85 | P2RX1 (0.48) | P2RY2 | |
| SCHEMBL19590286 | 0.84 | FUT5 (0.49) | POLGFUT5TGM2PNPNT5E | |
| SCHEMBL19590344 | 0.84 | NT5E (0.43) | TGM2PNPNT5ESTING1 | |
| SCHEMBL18877406 | 0.84 | POLG (0.47) | POLGFUT5TGM2PNPNT5E | |
| SCHEMBL20017108 | 0.83 | POLG (0.46) | POLGFUT5TGM2PNPNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307439-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10307439-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, TYMP | POLG 956/4885FUT5 124/4885TGM2 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.